You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 25, 2024

Claims for Patent: 4,216,211

✉ Email this page to a colleague

« Back to Dashboard

Summary for Patent: 4,216,211

Title:	Therapeutic composition
Abstract:	Phosphonate compounds are employed in the treatment of hypoxias and ischemic tissue diseases.
Inventor(s):	Francis; Marion D. (Cincinnati, OH)
Assignee:	The Procter & Gamble Company (Cincinnati, OH)
Application Number:	05/847,190
Patent Claims:	1. A process for increasing the level of 2,3-diphosphoglycerate in the blood of a human or lower animal in need of such treatment, comprising administering to said human or lower animal sufficient organophosphonate compound selected from the group consisting of vicinal organophosphonates of the formula ##STR4## and geminal organophosphonates of the formula ##STR5## and pharmaceutically acceptable salts thereof, wherein n is an integer from 1 to about 10; R, R.sub.1 and R.sub.2 are H,--CH.sub.2 OH, C.sub.1 -C.sub.20 alkyl or cycloalkyl, C.sub.2 -C.sub.20 alkenyl, aryl, phenylethyl, benzyl, halogen, amino, substituted amino, --CH.sub.2 COOH, --CH.sub.2 PO.sub.3 H.sub.2, --CH(PO.sub.3 H.sub.2) (OH) or --CH.sub.2 CH(PO.sub.3 H.sub.2).sub.2 ; R.sub.3 is H, C.sub.1 -C.sub.20 alkyl or cycloalkyl, C.sub.2 -C.sub.20 alkenyl, aryl, phenylethyl, benzyl, halogen, amino, substituted amino, --CH.sub.2 COOH, --CH.sub.2 PO.sub.3 H.sub.2, --CH(PO.sub.3 H.sub.2) (OH) or --CH.sub.2 CH(PO.sub.3 H.sub.2).sub.2 ; and R.sub.4 is H, lower alkyl, amino, benzyl, halogen, OH, --CH.sub.2 COOH, --CH.sub.2 PO.sub.3 H.sub.2 or --CH.sub.2 CH.sub.2 PO.sub.3 H.sub.2 to increase the blood level of said 2,3-diphosphoglycerate. 2. A process according to claim 1 wherein the organophosphonate compound is a member selected from the group consisting of ethane-1-hydroxy-1,1-diphosphonic acid and the pharmaceutically-acceptable salts and esters thereof. 3. A process according to claim 2 wherein the organophosphonate compound is a sodium salt of ethane-1-hydroxy-1,1-diphosphonic acid. 4. A process according to claim 1 wherein the organophosphonate compound is a member selected from the group consisting of methanediphosphonic acid and the pharmaceutically-acceptable salts and esters thereof. 5. A process according to claim 1 wherein the organophosphonate compound is a member selected from the group consisting of methanedichlorodiphosphonic acid and the pharmaceutically-acceptable salts and esters thereof.

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.